Oric Pharmaceuticals Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Yes. So Jacob, ORIC has a diverse portfolio of oncology drugs and then an interesting history, I think. Just remind us of the overall business model, and guiding principles of each strategy?

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : That makes sense. And then let's talk about some of your pipeline drugs. ORIC-101, your GR antagonist, is most advanced. You're in Phase 1b/2 studies now in -- either in combination with Xtandi in prostate cancer, and also in combination with chemo in other cancers. So perhaps just talk about the opportunity for ORIC-101, and how you think about GR as a drug target.

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Yeah. Okay, cool, that's really helpful. And then we've seen data from both programs this past year. Just remind us of the learnings, where you're in the study now, and what investors should expect for the upcoming updates?

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Okay, super. And yeah, we did speak offline a couple of weeks back. But just remind folks, perhaps maybe starting with a chemo combo which is the more complex study with three cohorts, first, briefly, how you selected the cohorts, and then what are you really looking forward to to advance into next steps. What gives you confidence in terms of data?

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Yeah, that makes sense. And then what about prostate in total? Are we looking for PSA response in a certain level there?

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Okay, yeah. That's very clear, so thanks for that. And then yeah, I did want to spend a couple minutes on your other pipeline programs, perhaps starting with ORIC-533. So there are -- all three of them are about to, or in Phase 1 at this point. So on ORIC-533, there are a number of different approaches addressing the adenosine signaling pathway. CD73 is one that has emerged as more interesting recently in addition to A2A. Talk about your choice of CD73, the level of validation of the target, and how you're thinking about the development of ORIC-533.

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Okay, that should be very interesting. And yeah, AZ also just initiated a Phase 3 trial based on that Coast data, so it's a nice additional validation there on the potential of [this class of drugs].

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : That makes sense. And then I am actually quite intrigued by ORIC-944, which is your PRC2 inhibitor. It's a mechanism that is less crowded. There's been a couple of EZH2 inhibitors, but that's about it. So maybe talk about what makes that particular drug interesting. And you're also going here into prostate cancer, and perhaps talk about that Phase 1 study.

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : Very interesting. And then last but not least, you also have an Exon 20 Inhibitor. It's getting a bit more crowded out there with Exon 20 Inhibitors in general. I guess, how is yours different and where do see the opportunity?

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : All right, super. And that's a good thought to close. But perhaps just last but not least, maybe, Dominic, if you want to wrap up with your cash runway at the moment, and to summarize again on the catalyst flow over the rest of the quarter.

Question: Michael Schmidt - Guggenheim Partners, LLC - Analyst : All right, very good. Well, with that, we'll conclude. Thank you, Dominic and Jacob, really appreciate it.